PROSTATE-SPECIFIC ANTIGEN

The Access Hybritech PSA assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of total prostate specific antigen (PSA) levels in human serum, using the Access Immunoassay Systems. This assay is indicated for the measurement of serum PSA in conjunction with digital rectal examination (DRE) as an aid in the detection of prostate cancer in men aged 50 years or older. This assay is further indicated for the serial measurement of PSA to aid in the prognosis and management of patients with prostate cancer.

		No.	0-4.0	4.01-10.0	10.01-20.0	20.01-40.0	>40.01
Healthy Subjects							
Men < 40 Years		265	100%	0%	0%	0%	0%
Men > 40 Years		207	97%	3%	0%	0%	0%
Total		**472**	**99%**	**1%**	**0%**	**0%**	**0%**
Cancerous Diseases							
Prostate:	Stage T1	70	37%	33%	13%	6%	11%
	Stage T2	90	29%	21%	12%	8%	30%
	Stage T3	128	19%	9%	10%	13%	49%
	Stage T4	265	12%	9%	11%	9%	59%
Total Prostate		**553**	**19%**	**14%**	**11%**	**10%**	**46%**
Gastrointestinal		187	95%	5%	0%	0%	0%
Genitourinary		323	98%	2%	0%	0%	0%
Mammary		91	99%	1%	0%	0%	0%
Pulmonary		147	95%	5%	0%	0%	0%
Renal		54	96%	4%	0%	0%	0%
Other		114	95%	5%	0%	0%	0%
Total Non-Prostate		**916**	**97%**	**3%**	**0%**	**0%**	**0%**
Non Cancerous Diseases							
Benign Prostatic Hypertrophy		352	80%	18%	2%	<1%	0%
Misc. Genitourinary		408	93%	7%	0%	0%	0%
Total		**760**	**87%**	**12%**	**<1%**	**<1%**	**0%**